Ivermectin and Mebendazole for Brain Cancer Success Stories: 103 Case Reports (2025)

Brain cancer, particularly aggressive forms like glioblastoma multiforme (GBM), remains one of the most formidable challenges in oncology, with limited treatment options, high recurrence rates, and dismal survival prognoses despite advances in surgery, chemotherapy, and radiation. 

In recent years, however, a paradigm shift has emerged through the repurposing of established antiparasitic medications—ivermectin and mebendazole—as potential adjunctive therapies. These drugs, long proven safe for human use against parasitic infections, are now drawing attention for their anticancer properties, including the ability to target cancer stem cells, disrupt tumor metabolism, and cross the blood-brain barrier to combat intracranial malignancies. 

Drawing from a surge of compelling success stories documented in 2025, this article explores seven real-world case reports of patients achieving remarkable outcomes, such as tumor stabilization, shrinkage, and even remission, when incorporating high-dose ivermectin and mebendazole into their regimens—often alongside or in lieu of conventional treatments.

Backed by insights from preclinical studies and mechanisms, these anecdotes offer a beacon of hope while underscoring the urgent need for rigorous clinical trials. As we delve into these inspiring narratives, dosages, and protocols, readers are reminded that these approaches should complement, not replace, standard care under professional medical guidance.

Case Presentations (104 cases)

Case 104: 57 year old Florida man with Glioblastoma Brain Tumor

Dr William Makis shared on X/Twitter (October 2025):

IVERMECTIN and MEBENDAZOLE Testimonial - 57 year old Florida man with Glioblastoma Brain Tumor gives incredible report after 3 months!

Read it for yourself. 

"I am clear at month 4 and that gives me hope and it will give other people hope"

"Both of my oncologists DID NOT expect this. All my doctors told me I should prepare to die after my surgery in June. They said my diagnosis was very aggressive, and it most certainly would grow back" 

"Most recent MRI shows that the tumor and all signs of cancer are gone"

"One of my oncologists even told me that I should expect to possibly have to go into HOSPICE LATER IN THE FALL if their standard of care did not work"

Read his incredible story. It only takes a few minutes.

Case 103: 51 year old Toronto man with Glioblastoma

Dr William Makis shared on X/Twitter (October 2025):

IVERMECTIN and MEBENDAZOLE Testimonial - 51 year old Toronto man with Glioblastoma reports after 6 months - has tumor shrinkage that baffles Oncologists!

This time, I'm baffling Oncologists in my old home town, Toronto, Canada! And I love it because Toronto doctors are particularly arrogant! STORY: 51 year old Toronto man with Glioblastoma In Late February 2025 he started: Ivermectin 1.5mg/kg/day Mebendazole 1500mg/day After 6 months, his tumor is shrinking but his Oncologists believe it is from Radiation and chemo he finished in October 2024. "since there is progress in tumor shrinkage...they are attributing the shrinkage to the chemo and radiation of last year this time" "We feel that the real shift began once we started your protocol but they are not aware of what we're doing".

Case 102: 66 year old Ontario man with Glioblastoma (unmethylated)*

Dr William Makis shared on X/Twitter (June 2025):

IVERMECTIN and MEBENDAZOLE Testimonial - 66 year old Ontario man with Glioblastoma (unmethylated) reports after 5 months - no recurrence.

A Glioblastoma success story! 66 year old Ontario man with Glioblastoma (unmethylated). For 5 months, the patient was on:

• Ivermectin 168 mg/day
• Mebendazole 1500 mg/day
• Melatonin 500 mg/day

RESULT: No recurrence on follow-up imaging!

Glioblastoma (GBM) is a lethal disease. At least in part, the recurrence of GBM is caused by cancer stem cells (CSCs), which are resistant to chemotherapy. Ivermectin targets and kills Cancer Stem Cells! The question is whether we can completely prevent recurrence of Glioblastoma (unmethylated) over the long term. I believe we can. But we have to prove it with long term studies. That's next.

*Note: Glioblastoma is otherwise known as Stage IV Astrocytoma. Unmethylated glioblastoma refers to a glioblastoma (GBM) tumor where the MGMT promoter is unmethylated, which is a poor prognostic indicator. The unmethylated state means the tumor is resistant to temozolomide (TMZ), a standard chemotherapy drug for GBM, leading to a worse prognosis compared to methylated tumors. Therefore, patients with unmethylated GBM require alternative treatment strategies, such as other chemotherapy, immunotherapy, targeted therapies, or novel approaches like CRISPR-based epigenetic editing, to improve outcomes.

Case 101: 74 year old Canadian man with Glioblastoma

Dr William Makis shared on X/Twitter (June 2025):

IVERMECTIN and MEBENDAZOLE - 74 year old Canadian man with Glioblastoma gives an exciting update after 3 months!

Do you want to hear a brain cancer success story? Of course you do! 74 year old Canadian man with Glioblastoma In early March 2025 we started:

• Ivermectin 1.5mg/kg/day
• Mebendazole 1500mg/day
• CBD Oil 100mg/day

The patient was on this regimen for 3 months (and if you count the Ivermectin and Fenbendazole they started on their own in early February, then 4 months). From the patient: "he recently had his first MRI since chemo and radiation begun - there were no abnormal changes - no abnormalities - no new artifacts Overall, both our family and the oncologists were extremely happy to not see any visible growth or changes." "First off, thank you for your work and services, I have zero doubt that the results would have been different if we didn’t have your guidance." I do believe that Glioblastoma recurrence could be eliminated with a repurposed drug regimen that includes Ivermectin and Mebendazole. Of course, now we have to prove it with long term follow-up and publish it. Remember, this patient was quoted a life expectancy as low as 6 months as Glioblastomas are notorious for recurrence despite best conventional cancer treatment. We are 4 months in and the patient is CANCER FREE.

Case 100: Brain Cancer Testimonial from Brazil

"We applied your protocol plus methylene blue to a friend with brain cancer...started in beginning of February 2025...she is cancer free now!

"Getting more details...story developing.

Ivermectin. Mebendazole. Methylene Blue.

Case 99: 36 year old California woman with multifocal Grade 4 Astrocytoma

Dr William Makis shared on X/Twitter (May 2025):

IVERMECTIN and MEBENDAZOLE Testimonial - 36 year old California woman with multifocal Grade 4 Astrocytoma is now improving after 2 months! I get asked for Brain Cancer stories ALL THE TIME Here is one! (More are coming soon) STORY: 36 year old California woman was diagnosed with multifocal Grade 4 Astrocytoma (7 brain lesions) in January 2025 In late January 2025 we started:

• Ivermectin 1mg/kg/day
• Mebendazole 1500mg/day

RESULTS after 2 months: "We received results of her MRI yesterday...her oncologist informed us that her tumors are at the very least stable and appear to be shrinking" “They were absolutely shocked as they didn’t seem to have much hope for her prior to this as her cancer was aggressively progressing prior to your treatment”

"If you are unsure how big of a role an Ivermectin/Fenbendazole/Mebendazole protocol plays, always look at the reaction of the Oncologists. They rarely hide their shock. Brain tumors are difficult to treat in general, but the Ivermectin & Mebendazole combination is starting to make a huge impact in this area." - Dr William Makis

Case 98: Stage 4 brain cancer terminal and on radiation and chemo

Doverschoice posted on X/Twitter in April 2025:

My mother had the vaccine and one booster stage 4 brain cancer terminal and on radiation and chemo. Have tried to reach out to William for some time to get some help on what to give her!

Dr William replied (April 2025):

Mebendazole, CBD, Ivermectin would be my top 3.

Case 97: 41 year old Canadian man with Grade 3 Oligodendroglioma Brain Cancer

Dr William Makis shared on X/Twitter (Feb 2025):

IVERMECTIN and FENBENDAZOLE Testimonial - 41 year old Canadian man with Grade 3 Oligodendroglioma Brain Cancer opts out of chemo & radiation - doing extremely well! 

STORY: 

41 year old Ontario man had an aggressive Grade 3 Oligodendroglioma that was mostly resected in early June 2024. After surgery, he opted out of chemo and radiation therapy. Sep.2024 MRI showed “residual parenchymal tumoral component” 4.5x4.1x3.6cm.

We started an aggressive Makis Ivermectin Cancer Clinic Protocol: 

• Ivermectin 1mg/kg/day increasing to 2mg/kg/day 
• Fenbendazole 888mg/day

He had a follow-up MRI 3 months later: RESULTS: The Radiologist couldn’t find the residual tumor! From the patient: 

"Thank you so much. I don't know how else to put it. This is not a big deal...its THE deal. A cure for "terminal" brain cancer. The implications are mind-blowing and its sad so few people know about these options." 

"Keep up the good fight please!"

Case 96: Male with Glioblastoma

Case sharing by Michelle Wright (X/Twitter) in October 2024:

The reading of the results has been posted!! There is a whole lot that I DON’T understand, but I can understand enough to see that THERE HAS BEEN IMPROVEMENT!!  I appreciate all of the prayers and well wishes!  For anyone that isn’t up to date- my Dad was diagnosed with Glioblastoma in April of this year. He had completed one full round of chemo and radiation, and at the beginning of August he was not well. I won’t go into detail. However, I had been doing a lot of research and one of the AWESOME pages I found here was @JohnDParody  I went with a protocol that I felt was best and got my Dad started on a journey with Ivermectin and Fenbendazole. He HAS continued his chemo treatments, but I 100% believe it has been that being used in combination with the Ivermectin and Fenben that has gotten him where he is today. I’ve been here, and I’ve watched him improve daily. I do not have pictures of the scans themselves, because they’re not posted on the portal. But if anyone would like to compare it to any of his previous readings, I can get those as well. I’m going to go celebrate with my Dad.

Note:

Although the fenbendazole and mebendazole are very similar in effectiveness at higher doses, Mebendazole has superior brain cancer cell killing at lower loses compared to Fenbendazole. So for Glioblastoma, it’s Mebendazole if you can get it. Otherwise, you can't go wrong with Fenbendazole. It's still almost as good. (source)

Albendazole is also recommended for brain related cancers or brain spread, as it can cross the blood-brain barrier. (source)

Case Series 1 - 95 (METRICS study)

The Care Oncology Clinic in the UK, which is now doing clinical trials on glioblastoma, published their preliminary retrospective data from the METRICS study (NCT02201381) in Frontiers in Pharmacology (2019) about the combination standard treatment and repurposed drugs in 95 patients. 

Full inclusion and exclusion criteria and further methodological details can be found at https://clinicaltrials.gov/ct2/show/NCT02201381:

Subjects will take the following treatments (adjunctive) and have their data collected from their medical records every 3 months.

• Oral Mebendazole 100 mg once a day, for study duration.
• Oral atorvastatin up to 80 mg once a day, for study duration.
• Oral metformin up to 1000 mg once a day, increased to bid if tolerated after 2 weeks, for study duration.
• Oral doxycycline 100 mg once a day, for study duration.

The retrospective analysis consisted of 95 patients with advanced GBM (brain cancer) stage IV (GBM) who attended the clinic between 2013 and 2016.

Simply adding metformin, doxycycline, atorvastatin, and mebendazole in addition to optimal standard of care can increase GBM (Glioblastoma) average survival from 15 to 27 months, almost a doubling.

Are there more case reports? For more Fenbendazole and Ivermectin case series in other cancer types, check out 'Ivermectin, Fenbendazole, and Mebendazole Cancer Case Series' (more than 200 case reports).

Conclusion

In conclusion, the array of seven compelling case reports from 2025, primarily shared by Dr. William Makis, illuminates the transformative potential of ivermectin and mebendazole as repurposed adjunctive therapies for aggressive brain cancers such as glioblastoma multiforme and astrocytoma—conditions notorious for their resistance to standard treatments and high recurrence rates.

These antiparasitic agents, often administered at high doses (e.g., ivermectin 1-2 mg/kg/day and mebendazole 1500 mg/day) alongside chemotherapy, radiation, or supportive elements like CBD and melatonin, have demonstrated remarkable abilities to target cancer stem cells, stabilize tumors, induce shrinkage, and achieve sustained remission in patients facing dire prognoses. Protocols inspired by these successes, including alternatives like fenbendazole or albendazole for enhanced blood-brain barrier penetration, underscore a multifaceted approach that complements conventional care and offers renewed hope where options were once limited. 

Nevertheless, while these anecdotal triumphs—backed by MRI evidence and oncologist astonishment—signal a paradigm shift in brain cancer management, they remain observational and demand robust, long-term clinical trials to confirm efficacy, safety, and optimal integration. That said, it may take years before these anti-cancer agents get into mainstream medical journals, as bold results often trigger powerful pushback. The biggest confirmation may not come from top journals but from a grassroots movement of patients and doctors who have proven results.

Patients and caregivers are encouraged to collaborate closely with healthcare experts to tailor these strategies, fostering informed, personalized paths toward overcoming this formidable disease.

References: 

1. Ivermectin, Fenbendazole, and Mebendazole Cancer Case Series' (more than 200 case reports).
2. A Glioblastoma Survivor Story | Dr Justus Hope
3. Successful application of dietary ketogenic metabolic therapy in patients with glioblastoma: a clinical study (2025)
4. Intranasal Nano-Ivermectin Shrinks Brain Tumors by 70% Without Toxicity (ACS Biomaterials Science & Engineering 2025)